13. 多発性硬化症／視神経脊髄炎 Multiple sclerosis/Neuromyelitis optica Clinical trials / Disease details
臨床試験数 : 3,340 / 薬物数 : 2,163 - (DrugBank : 383) / 標的遺伝子数 : 241 - 標的パスウェイ数 : 238
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05081700 (ClinicalTrials.gov) | May 11, 2020 | 13/11/2020 | A Systems Approach to Understanding Disease Processes in Multiple Sclerosis | A Systems Approach to Understanding Disease Processes in Multiple Sclerosis | Multiple Sclerosis | Drug: All patients in the study will be treated with ocrelizumab | Providence Health & Services | Institute for Systems Biology;Genentech, Inc. | Active, not recruiting | 18 Years | 60 Years | All | 14 | United States |